To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Public ClinicalTrials.gov record NCT05075408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Study identification
- NCT ID
- NCT05075408
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Galderma R&D
- Industry
- Enrollment
- 258 participants
Conditions and interventions
Interventions
- Nemolizumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2022
- Primary completion
- Jan 3, 2024
- Completion
- Jan 3, 2024
- Last update posted
- Apr 30, 2026
2022 – 2024
United States locations
- U.S. sites
- 47
- U.S. states
- 18
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site 9989 | Bakersfield | California | 93309 | — |
| Galderma Investigational Site 9991 | Glendale | California | 91205 | — |
| Galderma Investigational Site 7018 | Glendale | California | 91206 | — |
| Galderma Investigational Site 7015 | La Palma | California | 90623 | — |
| Galderma Investigational Site 9996 | Los Angeles | California | 90048 | — |
| Galderma Investigational Site 9978 | Lynwood | California | 90262 | — |
| Galderma Investigational Site 7017 | Riverside | California | 92505 | — |
| Galderma Investigational Site 9973 | Tarzana | California | 91356 | — |
| Galderma Investigational Site 7028 | Victorville | California | 92392 | — |
| Galderma Investigational Site 9964 | Victorville | California | 92394-1868 | — |
| Galderma Investigational Site 7003 | Whittier | California | 90603 | — |
| Galderma Investigational Site 9971 | Denver | Colorado | 80230 | — |
| Galderma Investigational Site 9988 | Bloomfield | Connecticut | 06002 | — |
| Galderma Investigational Site 9980 | Middlebury | Connecticut | 06762 | — |
| Galderma Investigational Site 9970 | Boca Raton | Florida | 33421 | — |
| Galderma Investigational Site 7037 | Coral Gables | Florida | 33134 | — |
| Galderma Investigational Site 7026 | Hollywood | Florida | 33021 | — |
| Galderma Investigational Site 9965 | Miami | Florida | 33125 | — |
| Galderma Investigational Site7016 | Miami | Florida | 33155 | — |
| Galderma Investigational Site 7032 | Sanford | Florida | 32771 | — |
| Galderma Investigational Site 7004 | Tampa | Florida | 33603 | — |
| Galderma Investigational Site 7025 | Tampa | Florida | 33603 | — |
| Galderma Investigational Site 7027 | Columbus | Georgia | 31904 | — |
| Galderma Investigational Site 9983 | Overland Park | Kansas | 66210 | — |
| Galderma Investigational Site 9972 | Wichita | Kansas | 67214 | — |
| Galderma Investigational Site 9963 | Roseville | Michigan | 48066 | — |
| Galderma Investigational Site 7020 | Edina | Minnesota | 55435 | — |
| Galderma Investigational Site 9982 | Minneapolis | Minnesota | 55404 | — |
| Galderma Investigational Site 7035 | Kansas City | Missouri | 64111 | — |
| Galderma Investigational Site 9962 | Las Vegas | Nevada | 89128 | — |
| Galderma Investigational Site 7038 | Fresh Meadows | New York | 11365 | — |
| Galderma Investigational Site 9998 | Great Neck | New York | 11021 | — |
| Galderma Investigational Site 9995 | The Bronx | New York | 10461 | — |
| Galderma Investigational Site 7007 | Winston-Salem | North Carolina | 27103 | — |
| Galderma Investigational Site 9992 | Roseburg | Oregon | 97471 | — |
| Galderma Investigational Site 9999 | Spartanburg | South Carolina | 29306 | — |
| Galderma Investigational Site 9967 | Chattanooga | Tennessee | 37404 | — |
| Galderma Investigational Site 7039 | Arlington | Texas | 76015 | — |
| Galderma Investigational Site 7040 | Dallas | Texas | 75231 | — |
| Galderma Investigational Site 9966 | El Paso | Texas | 79925 | — |
| Galderma Investigational Site 9977 | Greenville | Texas | 75402 | — |
| Galderma Investigational Site 7011 | Houston | Texas | 77054 | — |
| Galderma Investigational Site 7022 | McKinney | Texas | 75069 | — |
| Galderma Investigational Site 7010 | San Antonio | Texas | 78258 | — |
| Galderma Investigational Site 7019 | The Woodlands | Texas | 77384 | — |
| Galderma Investigational Site 9968 | Norfolk | Virginia | 23502 | — |
| Galderma Investigational Site 9969 | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05075408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05075408 live on ClinicalTrials.gov.